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Abstract
Background and aims: Buprenorphine is an effective medication for opioid use disorder
that reduces mortality; however, many patients are not retained in buprenorphine treatment, and an optimal length of treatment after which patients can safely discontinue
treatment has not been identified. This study measured the association between buprenorphine treatment duration and all-cause mortality among patients who discontinued
treatment. Secondary objectives were to measure the association between treatment
duration and drug overdose and opioid-related overdoses.
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Design: Multi-site cohort study.

6

Participants: Patients who initiated and discontinued buprenorphine treatment
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Setting: Eight US health systems.
between 1 January 2012 and 31 December 2018 (n = 6550). Outcomes occurring after
patients discontinued buprenorphine treatment were compared between patients who
initiated and discontinued treatment after 8–30, 31–90, 91–180, 181–365 and
> 365 days.
Measurements: Covariate data were obtained from electronic health records (EHRs).
Mortality outcomes were derived from EHRs and state vital statistics. Non-fatal opioid
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and drug overdoses were obtained from diagnostic codes. Four sites provided cause-ofdeath data to identify fatal drug and opioid-related overdoses. Adjusted frailty regression

Center for Health Policy and Health Services
Research, Henry Ford Health System, Detroit,
MI, United States

was conducted on a propensity-weighted cohort to assess associations between dura-
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Findings: The mortality rate after buprenorphine treatment was 1.82 per 100 person-
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tion of the final treatment episode and outcomes.
years (n = 191 deaths). In regression analyses with > 365 days as the reference group,
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treatment duration was not associated with all-cause mortality and drug overdose
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(P > 0.05 for both). However, compared with > 365 days of treatment, 91–180 days of
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treatment was associated with increased opioid overdose risk (hazard ratio = 2.94, 95%
confidence interval = 1.11–7.79).
Conclusions: Among patients who discontinue buprenorphine treatment, there appears
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to be no treatment duration period associated with a reduced risk for all-cause mortality.
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I N T R O D U CT I O N

commercially insured, Medicaid and Medicare populations. A propensity score analytical approach with inverse probability weighting was

Buprenorphine is an effective treatment for opioid use disorder

used to control for confounding. We hypothesized that mortality risk

(OUD) that reduces the risk of recurrence of opioid use, overdose

after buprenorphine discontinuation would increase with shorter

and death [1–5]. People who discontinue treatment are at

buprenorphine treatment duration prior to discontinuation. As sec-

increased risk for overdose and all-cause mortality, particularly in

ondary objectives, we examined associations between buprenorphine

the first 4 weeks after ceasing treatment [1, 6]. As a result, the

treatment duration and risks of fatal and non-fatal opioid and drug

American Society of Addiction Medicine and the Substance Abuse

overdoses (also called poisonings) after treatment discontinuation.

and Mental Health Services Administration do not recommend a

We

limit on the time patients remain on buprenorphine treatment

the Reporting of Observational Studies in Epidemiology (STROBE)

[7, 8]. Retaining patients on buprenorphine treatment, however, is

statement.

followed

reporting

guidelines

from

the

Strengthening

difficult [2, 9–12]. At treatment onset, more than a quarter of
patients report that they do not want to stay on buprenorphine
treatment for more than 6 months [13], and approximately 40%

METHODS

of patients who initiate treatment discontinue within 6 months
[14, 15]. Patients may voluntarily discontinue because of other life

Study settings, data sources and data elements

obligations or dissatisfaction with the medication, or they may be
involuntarily discontinued because of conflicts with program staff,

The study (CTN-0084A1) was conducted using data from the Opioid

difficulty adhering with program requirements, substance use or

Registry (CTN-0084) of the Health Systems Node, a multi-site collab-

incarceration [13].

oration funded by the National Institute on Drug Abuse, National

At present, a time-period after which patients can safely discon-

Drug Abuse Treatment Clinical Trials Network (CTN). The following

tinue buprenorphine treatment has not been established. Treatment

eight health system sites participated in the study: Geisinger Health

durations of greater than a year have been associated with reduced

System (Pennsylvania); the Henry Ford Health System (HFHS, Michi-

emergency department (ED) and inpatient utilization [16], but the

gan); Kaiser Permanente Colorado (KPCO); Kaiser Permanente Mid-

effect of treatment duration on mortality risk is not known.

Atlantic States (KPMAS, Maryland, Virginia, and Washington, DC);

Randomized clinical trials could help to identify an optimal duration of

Kaiser Permanente Northern California (KPNC); Kaiser Permanente

buprenorphine treatment, but such studies may face ethical

Northwest (KPNW, Oregon); Kaiser Permanente Southern California

challenges and enroll participants who do not necessarily represent

(KPSC); and Meyers Primary Care Institute (MPCI, for Fallon Health,

the overall population of patients indicated for treatment. To address

Massachusetts). Each health system site represented an integrated

this gap in research, we conducted a multi-site cohort study to exam-

health insurance plan and care delivery system serving between

ine the association between duration of buprenorphine treatment and

approximately 270 000 and 4.7 million patients among multiple

mortality among patients who discontinued treatment. Participating

clinics, pharmacies and hospitals. Each site delivered OUD treatment

sites represent a diverse group of health systems that provide care for

through internal or contracted specialty addiction treatment programs
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and, in some cases, primary care. All sites provided sublingual bupre-

limited the cohort to patients who had discontinued buprenorphine

norphine or buprenorphine/naloxone (hereafter referred to as bupre-

treatment at some point throughout the follow-up. Patients who were

norphine), oral and intramuscular naltrexone, and referrals to

still receiving treatment at the end of 2018 were not included.

externally licensed methadone treatment programs.

Buprenorphine treatment during the study period was catego-

Each site created standardized data sets derived from the Opioid

rized into treatment episodes. Distinct treatment episodes were sepa-

Registry, a harmonized, distributed registry maintained locally at each

rated by buprenorphine dispensing gaps of 28 days or more [17].

health system site. The Opioid Registry includes electronic health

Patients could have multiple treatment episodes throughout the

record (EHR), automated pharmacy records, membership/enrollment

follow-up. Treatment episodes of fewer than 8 days were excluded,

and mortality data tables. All patients with at least one opioid dis-

as these patients probably had an unsuccessful induction onto bupre-

pensation or a diagnosis of OUD between 2012 and 2018 were

norphine. We also excluded treatment episodes interrupted by disen-

included in the registry. The following data elements were used for

rollment from the health plan, death, hospice or a cancer diagnosis.

study eligibility, covariates and outcomes: demographic variables

The ending date of a buprenorphine treatment episode—the date

(sex, age, race and ethnicity); types of insurance (commercial, Medi-

when the patient discontinued buprenorphine treatment—was consid-

care and Medicaid); insurance enrollment dates; medical encounters

ered the index date. Patients with multiple treatment episodes sepa-

in the outpatient, inpatient and ED settings; and outpatient dis-

rated by 28 or more days had multiple index dates. For patients with

pensed medications including dose and days’ supply. National drug

multiple treatment episodes, the primary analysis focused upon the

codes (NDC) were used to identify buprenorphine, antidepressants,

final treatment episode during the study period; time on treatment

gabapentin, zolpidem, eszopiclone, zaleplon and benzodiazepines.

was not summed across treatment episodes unless the gap was less

Procedure claims codes were used to identify methadone treatment

than 28 days. We analyzed the final treatment episode during the

(Supporting information, Table S2 lists procedure codes used)

study period to avoid biasing results in favor of shorter treatment epi-

because methadone for opioid use disorder treatment occurs in

sodes. For example, among the patients with more than one treat-

externally licensed treatment centers. Naltrexone was identified with

ment episode the initial episode, was on average, 30 days shorter

both NDC and procedure codes. Diagnoses were identified using

than the final treatment episode. These patients probably required

International Classification of Disease (ICD)-9 and -10 codes

multiple treatment episodes to treat their opioid use disorder because

(Supporting information, Table S1 lists ICD codes used) or tumor reg-

the earlier episodes were not fully effective. Patients with multiple

istries. All sites provided data on death and date of death recorded

treatment episodes also could not have died between treatment epi-

in the EHR, including deaths that occurred in the ED or hospital or

sodes during the study period. Including earlier treatment episodes in

that were reported to the treating physician, health system or insur-

the analysis could therefore bias the results by underestimating the

ance plan (fact of death). For a subset of health systems (KPCO,

mortality rate following shorter treatment durations [17].

KPNW, KPNC and Henry Ford), state vital statistics offices supple-

After buprenorphine discontinuation, follow-up started the day

mented EHR-based vital records with cause-of-death data. The other

after the index date and ended on the earliest occurrence of either

four sites were not able to contribute cause of death data due to

death, disenrollment, a switch to methadone or naltrexone treatment

privacy policies.

or 31 December 2018. We censored follow-up at a switch to metha-

Approval to conduct this study was granted by the KPNC Institutional Review Board (IRB), with each of the other sites’ IRBs ceding
oversight to the KPNC IRB.

done or naltrexone treatment because they are known to affect mortality risk among patients with an opioid use disorder [5, 18].
Although the primary analysis focused on the final treatment episode during the study period, it is possible that this could introduce a
bias favoring longer treatment episodes. We therefore conducted a

Study design and population

sensitivity analysis that included all treatment episodes during the
study period.

We conducted a retrospective cohort study of patients aged 18 years
and older who had initiated and discontinued buprenorphine treatment. We first identified patients who had initiated treatment

Exposure groups, outcomes and covariates

between 1 January 2012 and 31 December 2017. These patients had
to have at least 90 days of continuous insurance enrollment prior to

Patients who initiated and discontinued buprenorphine treatment

their first buprenorphine dispensing and at least 1 day of insurance

were divided into five groups based on clinically relevant durations of

enrollment after discontinuing buprenorphine. Requiring 90 or more

time on buprenorphine treatment: 8–30, 31–90, 91–180, 181–365

days of enrollment helped to ensure adequate capture of covariate

and > 365 days. These time-periods were selected to capture the

data and to ensure an accurate assignment of the treatment start

evolving intensity of clinical monitoring over time on treatment. Early

date, as patients could enter the health plan already receiving bupre-

in treatment, programs may provide more frequent visits (e.g. weekly),

norphine treatment. Patients with self-funded insurance or insurance

request more frequent urine drug toxicology and provide smaller sup-

without pharmacy coverage were excluded. Patients were followed

plies of medication, whereas, after patients appear stable, programs

from inclusion in the study sample until 31 December 2018. We then

may provide less frequent visits, request less frequent toxicology and
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provide longer medication supplies [7, 19]. The periods were also

(i.e. potential confounders). To determine which covariates were asso-

selected to ensure that we captured early treatment discontinuation,

ciated with treatment duration, we conducted univariate multinomial

as the median length of treatment observed was 36 days [interquartile

logistic regressions with the five treatment duration categories as the

range (IQR) = 19, 137].

dependent variable and each covariate as the independent variable.

Outcomes were assessed in the post-discontinuation follow-up

For all-cause mortality, we conducted univariate Cox proportional

time (i.e. after the index date). For our primary outcome, we examined

hazard regressions, with death as the dependent variable and each

all-cause mortality in all eight sites using deaths identified in each

covariate as the independent variable. To calculate the propensity

site’s opioid registry. As secondary outcomes, we examined non-fatal

scores and stabilized weights, covariates with P < 0.10 in both univari-

and fatal opioid overdoses and fatal and non-fatal drug overdoses in a

ate regression analyses were included in a single multivariable multi-

subset of four sites that had cause-of-death data available (see Sup-

nomial logistic regression model, with treatment duration group as the

porting information, Table S1 for ICD codes). Person-time was cen-

dependent variable. The weights were applied to the cohort, and

sored at the first overdose event after the last treatment episode;

covariate balance across treatment groups was assessed with popula-

patients could not experience multiple overdoses after the episode.

tion standardized mean differences (PSD) before and after propensity

We considered covariates that were either known to be associ-

score weighting and with diagnostic plots. To calculate the PSDs, we

ated with buprenorphine retention based on prior studies or thought

set up separate bivariate comparisons for each covariate within each

to impact upon whether or not a patient was discontinued from treat-

of the five treatment groups (e.g. treatment duration of 8–30 days

ment [15, 20–22]. Demographic covariates included age, race and eth-

versus pooled population), resulting in five different comparisons for

nicity. We assessed several medication exposures as covariates,

each covariate [27]. For a given covariate, a PSD of less than 0.10 was

including dispensing of antidepressants, gabapentin, zolpidem, eszopi-

considered adequate balance [28].

clone, zaleplon and benzodiazepines in the 6 months prior to and

A time-to-event analysis was conducted on the propensity-

including the first day of the final buprenorphine treatment episode.

weighted cohort to assess the association between treatment dura-

We also considered prescription opioid dispensing in the 30 days prior

tion and primary and secondary outcomes. A buprenorphine treat-

to and including the first day of the final treatment episode, and the

ment duration of > 365 days served as the referent group for the

total number of prior buprenorphine treatment episodes. The follow-

five-level treatment duration variable. Frailty models were used to

ing clinical covariates were measured in the 6 months prior to and

estimate adjusted hazard ratios (aHRs) and 95% confidence intervals

including the first day of the final treatment episode: medical comor-

(CI) [29]. A frailty model is an extension of a Cox proportional hazards

bidity (captured with the Quan modification of the Charlson Comor-

model that incorporates random effects to account for the clustering

bidity Index) [23], number of prior ED visits, prior drug overdose,

of observations. Study site was included in the models as a random

severity of OUD diagnosis (mild/moderate, severe and unknown),

effect, and the maximum dispensed dose of buprenorphine (mg/day)

infections associated with injection drug use (e.g. infective endocardi-

was included in the model as a covariate. Variables from the propen-

tis, hepatitis B, abscess, cellulitis) [24], alcohol use disorder, non-

sity score analysis with PSDs greater than 0.10 across two or more of

opioid drug use disorders [9, 10, 14, 20] and mental health conditions

the treatment comparisons were included as covariates to account for

(schizophrenia and psychotic disorder, mood disorders including bipo-

residual confounding [28]. In post-hoc analyses, pairwise comparisons

lar, major depressive disorder and adjustment disorder with depressed

were conducted between the treatment duration groups without an

mood, anxiety and post-traumatic stress disorder, personality disor-

adjustment for multiple comparisons. We conducted two-sided statis-

ders and attention deficit hyperactivity disorders). We also assessed

tical tests with a P < 0.05 cut-off for statistical significance. The pro-

the maximum dispensed buprenorphine dose (milligrams per day) dur-

portional hazards assumption was evaluated with scaled Schoenfield

ing the final treatment episode; due to secular changes in OUD treat-

residuals plots and a global goodness-of-fit test. For age, the assump-

ment practices, we considered the calendar year that patients started

tion of linearity in the log hazard was assessed with a Kolmogorov-

their final treatment episode.

type supremum test in which a P-value was calculated based on a
sample of 1000 residual patterns [30]. A P-value < 0.05 indicates a
departure from linearity.

Analysis

Published studies have documented higher mortality in the first
4 weeks off treatment [5]; therefore, Kaplan–Meier curves for all-

Propensity score

cause mortality were generated to visually examine the survival probabilities across groups over time. We examined the first 180 days off

To account for the imbalance of covariates among the five buprenor-

treatment to visualize differences that occur early after treatment

phine treatment duration groups, we conducted a propensity score

discontinuation.

analysis and applied stabilized weighting. Stabilized weighting is an

As a sensitivity analysis, all treatment episodes during the study

improved version of inverse probability weighting (IPTW) that reduces

period were assessed in a frailty model. Individual patients were

the impact of observations with extreme IPTW values [25, 26].

included in the model as a random effect, which accounted for the

Among the covariates under consideration, we included those that

clustering of treatment episodes among individuals who had more

were associated with both treatment duration and all-cause mortality

than one episode. All-cause mortality, and fatal and non-fatal
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overdose rates were calculated between treatment episodes and after

episodes was 147 (IQR = 64–351). Approximately 46% of patients

the final episode. For fatal and nonfatal overdose, person-time was

(n = 3014) discontinued buprenorphine between 8 and 30 days after

censored at the fatal overdose, but individuals could experience recur-

initiating the final treatment episode.

rent non-fatal overdoses between multiple treatment episodes. Site

The mean age of the cohort was 36.8 years (SD = 14.7); 39.2% of

was included in the frailty model as a strata variable, and all the vari-

the patients were female, 72.5% were non-Hispanic white and 12.9%

ables described in the primary analysis were assessed as time-varying

were Hispanic (Table 1). Approximately 29% may have transitioned

covariates at or prior to each treatment episode.

from opioid analgesic use, based on receiving opioid dispensings in

®

All analyses were conducted using SAS Studio Software version
3.8 (SAS Institute Inc., Cary, NC, USA).

the month prior to starting buprenorphine. Most (82.3%) had
moderate-to-severe OUD diagnoses, and a majority (54.7%) had mental health diagnoses.
Among all eight health systems, 191 cohort members died after

RESULTS

discontinuing buprenorphine treatment (1.82 per 100 person-years;

Patient characteristics

received buprenorphine for 91 to 180 days (2.92 per 100 person-

Table 2). The highest crude mortality rate was among patients who
years). Among the sites with complete cause-of-death information
We identified 6550 patients who initiated and discontinued buprenor-

(n = 3934) the rate of fatal and non-fatal drug overdose was 5.55 per

phine treatment between 1 January 2012 and 31 December 2017,

100 person-years (n = 327), and approximately one-third were noted

and had at least 1 day of health plan enrollment after discontinuing

to be opioid-related (n = 109, 1.78 per 100 person-years). Among the

treatment (Figure 1). The number of buprenorphine treatment epi-

109 opioid overdoses from the four sites with cause-of-death data,

sodes ranged from one to 17 (median 1), but a majority of patients

80 (73.4%) were non-fatal and 29 (26.6%) were fatal. Similar to all-

(n = 4897, 74.8%) had a single treatment episode. The mean and

cause mortality, the highest overdose rates occurred among people

median times on treatment were 181.4 days [standard deviation (SD)

who were treated from 91 to 180 days (drug = 6.63 per 100 person-

= 289.6] and 60 days (IQR = 27–203), respectively. Among those with

years; opioid = 2.76 per 100 person-years).

multiple treatment episodes, the mean times on treatment for the initial and final episodes were 109.5 days (SD = 169.5) and 139.6 days
(SD = 237.3), respectively. The median times on treatment for initial

Propensity score weighting

and final episodes were 42 days (IQR = 22–126) and 40 days
(IQR = 21–141), respectively. The mean time between treatment epi-

In the univariate regression analyses, the following variables were

sodes was 264 days (SD = 298), and the median time between

associated with both treatment and all-cause mortality (P < 0.10): age,

FIGURE 1

Cohort diagram. a2228 (54%) also had at least one other exclusion criterion
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T A B L E 1 Unweighted characteristics of patients in eight health systems who discontinued buprenorphine between 2012 and 2018, by
buprenorphine treatment episode durationa
Buprenorphine treatment duration

Characteristic

All ≥ 8 days
(N = 6550)

8–30 days
(n = 3014)

31–90 days
(n = 1426)

91–180 days
(n = 768)

181–365 days
(n = 622)

≥ 366 days
(n = 720)

P-value

Age, mean (SD)

36.8 (14.7)

37.1 (15.5)

35.2 (13.8)

35.5 (13.5)

37.2 (13.8)

39.5 (14.6)

< 0.0001

Female

2568 (39.2)

1157 (38.4)

550 (38.5)

312 (40.6)

247 (39.7)

302 (41.9)

Male

3982 (60.8)

1857 (61.6)

876 (61.4)

456 (59.4)

375 (60.3)

418 (58.1)

Gender, n (%)

0.3941

Race/ethnicity, n (%)

< 0.0001

Black, non-Hispanic

337 (5.1)

181 (6.0)

59 (4.1)

35 (4.6)

25 (4.0)

37 (5.1)

Hispanic

848 (12.9)

449 (14.9)

186 (13.0)

75 (9.8)

68 (10.9)

70 (9.7)

221 (3.4)

106 (3.5)

46 (3.2)

22 (2.9)

30 (4.8)

17 (2.4)

Asian, Pacific Islander,
Native American and
Other non-Hispanic
Unknownb

395 (6.0)

165 (5.5)

108 (7.6)

61 (7.9)

36 (5.8)

25 (3.5)

White, non-Hispanic

4749 (72.5)

2113 (70.1)

1027 (72.0)

575 (74.9)

463 (74.4)

571 (79.3)

2012

789 (12.0)

361 (12.0)

192 (13.5)

91 (11.8)

64 (10.3)

81 (11.3)

2013

1063 (16.2)

485 (16.1)

233 (16.3)

118 (15.4)

91 (14.6)

136 (18.9)

2014

1072 (16.4)

500 (16.6)

211 (14.8)

123 (16.0)

102 (16.4)

136 (18.9)

2015

1138 (17.4)

535 (17.8)

249 (17.4)

123 (16.0)

109 (17.5)

122 (16.9)

2016

1237 (18.9)

557 (18.5)

250 (17.5)

156 (20.3)

118 (19.0)

156 (21.7)

2017

1251 (19.1)

576 (19.1)

291 (20.4)

157 (20.4)

138 (22.2)

89 (12.4)

1915 (29.2)

893 (29.6)

405 (28.4)

221 (28.8)

178 (28.6)

218 (30.3)

0.8617

42 (5.5)

27 (4.3)

37 (5.1)

0.8587

Year treatment episode started,a n (%)

Opioid dispensed in 30 days prior to
buprenorphine treatment
episode,a n (%)

0.0028

Medications dispensed in 6 months prior to buprenorphine treatment episodea
‘Z’ medications,c n (%)

315 (4.8)

141 (4.7)

Antidepressants, n (%)

3139 (47.9)

1394 (46.3)

700 (49.1)

370 (48.2)

321 (51.6)

354 (49.2)

0.0934

Gabapentin, n (%)

1083 (16.5)

476 (15.8)

216 (15.1)

159 (20.7)

122 (19.6)

110 (15.3)

0.0013

Benzodiazepines, n (%)

2106 (32.2)

957 (31.8)

483 (33.8)

256 (33.3)

197 (31.7)

213 (29.6)

0.3050

< 0.0001

68 (4.8)

Diagnoses in 6 months prior to buprenorphine treatment episodea
Opioid use disorder severity, n (%)d
No severity indicated

1032 (15.8)

603 (20.0)

181 (12.7)

82 (10.7)

78 (12.5)

88 (12.2)

Mild

126 (1.9)

44 (1.5)

29 (2.0)

12 (1.6)

15 (2.4)

26 (3.6)

Moderate/severe

5392 (82.3)

2367 (78.5)

1216 (85.3)

674 (87.8)

529 (85.0)

606 (84.2)

1208 (18.4)

514 (17.1)

268 (18.8)

159 (20.7)

115 (18.5)

152 (21.1)

0.0409

292 (4.5)

130 (4.3)

75 (5.3)

43 (5.6)

24 (3.9)

20 (2.8)

0.0452

3582 (54.7)

1638 (54.3)

798 (55.9)

422 (54.9)

333 (53.5)

391 (54.3)

0.8418

Alcohol use disorder, n (%)
Injection drug use
Infection,e n (%)
Mental health disorder, n (%)

Diagnoses any time prior to the final buprenorphine treatment episode
Drug use disorder,f n (%)

4249 (64.9)

1923 (63.8)

952 (66.8)

535 (69.7)

395 (63.5)

444 (61.7)

0.0042

Drug overdose, n (%)

684 (10.4)

322 (10.7)

144 (10.1)

106 (13.8)

57 (9.2)

55 (7.6)

0.0023

Emergency department visits in
6 months prior to treatment
episode, median number
[interquartile range (IQR)]

0 (0, 1)

0 (0, 1)

0 (0, 1)

0 (0, 0)

0 (0, 1)

0 (0, 1)

0.0204

Charlson Comorbidity Index,
median (IQR)

0 (0, 1)

0 (0, 1)

0 (0, 1)

0 (0, 1)

0 (0, 1)

0 (0, 1)

0.1526

(Continues)
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TABLE 1

(Continued)
Buprenorphine treatment duration
All ≥ 8 days
(N = 6550)

8–30 days
(n = 3014)

31–90 days
(n = 1426)

91–180 days
(n = 768)

181–365 days
(n = 622)

≥ 366 days
(n = 720)

P-value

Buprenorphine treatment episodes,
median number (IQR)

1 (1, 2)

1 (1, 2)

1 (1, 2)

1 (1, 2)

1 (1, 2)

1 (1, 2)

0.1940

Maximum buprenorphine dose
prescribed in final episode,
median mg/day (IQR)

12 (8, 16)

8 (6, 16)

12.6 (8, 16)

16 (8, 20.6)

16 (8.2, 22)

16 (12, 24)

< 0.0001

Switched to naltrexone or
methadone after buprenorphine
treatment episode, n (%)g

713 (10.9)

317 (10.5)

164 (11.5)

98 (12.8)

79 (12.7)

55 (7.6)

0.0090

Characteristic

a

If individuals had more than one treatment episode, the final one between 2012 and 2018 is described.
Unknown race was treated as a separate race/ethnicity category in the propensity score.
c
Includes zolpidem, eszopiclone and zaleplon.
d
Opioid severity was assessed in the 6 months prior to the final buprenorphine treatment episode, including the first day of the final treatment episode.
ICD-9 codes of 304.0, 304.7 or an ICD-10 code of F11.2 indicated moderate/severe opioid use disorder; ICD-9 code of 305.5 or ICD-10 code of F11.1,
F11.9 indicated mild opioid use disorder.
e
Includes skin or soft tissue infections, bacteremia or sepsis and osteomyelitis.
f
Alcohol, opioid abuse and tobacco were not included.
g
Patients were censored at the time they switched to naltrexone or methadone after stopping buprenorphine. SD = standard deviation.
b

T A B L E 2 Crude death and overdose rates after last buprenorphine treatment episode between 2012 and 2018, overall and by treatment
episode duration

Outcome event

Total person-years
after stopping final
treatment episode

All-cause mortality

Number of outcome events after each buprenorphine treatment duration prior to discontinuation
(crude event rate per 100 person years)
8–30 days

31–90 days

91–180 days

181–365 days

≥ 366 days

Overalla

10471.48

88 (1.60)

48 (2.10)

32 (2.92)

10 (1.21)

13 (1.72)

191 (1.82)

Non-fatal and fatal drug
overdoseb−d

5891.89

160 (5.79)

75 (5.75)

49 (6.63)

19 (3.43)

24 (4.56)

327 (5.55)

Non-fatal and fatal opioid
overdoseb,c,e,f

6111.70

54 (1.88)

23 (1.70)

21 (2.76)

6 (1.06)

5 (0.91)

109 (1.78)

a

If individuals had more than one treatment episode between 2012 and 2018, the final one is analyzed.
Limited to the four sites with cause-of-death data (n = 3934).
c
Person-time censored at first overdose event; patients could not experience more than one overdose in the analysis.
d
There were 281 patients who had a non-fatal drug overdose, and 46 who had a fatal drug overdose.
e
Opioid overdoses include heroin and pharmaceutical opioid overdoses and are a subset of drug overdoses.
f
There were 80 patients who had a non-fatal opioid overdose and 29 who had a fatal opioid overdose.
b

race/ethnicity, antidepressant use, gabapentin use, drug overdose

Analysis of primary and secondary outcomes

prior to treatment initiation, intravenous drug use infections, alcohol
use disorder, substance use disorder diagnosis, calendar year of final

In the fully adjusted and propensity-weighted model, no statistically

treatment and prior ED visits (Supporting information, Table S3).

significant association between the final buprenorphine treatment

These variables were included in a multivariable multinomial

length and all-cause mortality was observed, with > 365 days as

logistic regression model, with treatment duration group as the

the reference group (Figure 2). The aHRs were above 1.00 and

dependent

and

increased incrementally for treatment durations of 8–30 days

stabilized weights. After applying the weights and calculating PSDs,

(aHR = 1.25; 95% CI = 0.68–2.31), 31–90 days (aHR = 1.59; 95% CI

age had a PSD > 0.10 in two of the five treatment group comparisons,

= 0.85–2.98) and 91–180 days (aHR = 1.93; 95% CI = 1.00–3.71),

and was therefore included in the adjusted Cox regression models

and then dropped to below 1.00 for 181–365 days (aHR = 0.79;

(Supporting information, Figures S1–S5). Based on the diagnostic

95% CI = 0.35–1.82). The pairwise comparisons revealed two sta-

plots, the covariates appeared to be evenly balanced across the

tistically significant associations indicating higher risk with shorter

treatment groups.

treatment durations: treatment duration 31–90 days compared to

variable

to

calculate

the

propensity

scores
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F I G U R E 2 Adjusted hazard ratios representing the association between duration of buprenorphine treatment and all-cause mortality, drug
overdose or opioid overdose after the final treatment episode. aIf individuals had more than one treatment episode, the final one between 2012
and 2018 is analyzed. bLimited to the four sites with cause-of-death data (n = 3934). cPerson-time censored at first overdose event after the final
treatment episode; patients could not experience more than one overdose in the analysis. dOpioid overdoses include heroin and pharmaceutical
opioid overdoses and are a subset of drug overdoses. CI = confidence interval

181–365 days (aHR = 2.00; 95% CI = 1.01–3.98) and 91–180 days

For fatal and non-fatal opioid overdose, the aHRs were above

compared to 181–365 days (aHR = 2.42; 95% CI = 1.19–4.95;

1.00 for 8–30 days (aHR = 2.10; 95% CI = 0.82–5.34), 31–90 days

Table 3). Based on the Kolmogorov-type supremum test, the

(aHR = 1.85; 95% CI = 0.70–4.87), 91–180 days (aHR = 2.94; 95% CI,

assumption of linearity in the log hazard for age did not appear to

1.11–7.79) and 181–365 days (aHR = 1.19; 95% CI = 0.37–3.88).

be violated (P = 0.422).

None of the pairwise comparisons were statistically significant

Similar patterns were observed for the secondary outcomes of

(Table 3).

fatal and non-fatal drug and opioid overdoses (Figure 2). For

Kaplan–Meier survival curves (Supporting information, Figure S6)

fatal and non-fatal drug overdose, the aHRs were above 1.00 for

demonstrate that people treated for 365 days or more had a steeper

8–30 days

31–90 days

drop in survival during the first 30 days after treatment, whereas the

(aHR = 1.30; 95% CI = 0.82–2.07) and 91–180 days (aHR = 1.48,

patients treated for 91–180 days had lower survival than other

95%

groups after 120 days.

CI,

(aHR = 1.39;
0.91–2.42),

95%

and

CI = 0.89–2.16),

then

dropped

below

1.00

for

181–365 days (aHR = 0.74; 95% CI = 0.41–1.36). The pairwise

In the sensitivity analysis that included all treatment episodes,

comparisons revealed three statistically significant associations for

there were no statistically significant associations between buprenor-

drug

to

phine treatment length and all-cause mortality, fatal and non-fatal

31–90 days

drug overdose or fatal and non-fatal opioid overdose (Table 4). For all-

compared to 181–365 days (aHR = 1.75; 95% CI = 1.05–2.91) and

cause mortality, the aHRs demonstrated a similar pattern to that of

91–180 days

the primary analysis, but the associations were attenuated by approxi-

overdose:

181–365 days

treatment
(aHR = 1.86;

compared

CI = 1.17–3.40) (Table 3).

to

duration
95%

8–30 days

compared

CI = 1.14–3.04),

181–365 days

(aHR = 1.99;

95%

mately 12 to 16%.
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T A B L E 3 Post-hoc analyses showing adjusted pairwise comparisons between different buprenorphine treatment durations with all-cause
mortality, drug overdose or opioid overdose after discontinuing buprenorphine
Adjusted hazard ratio (95% CI)
Days of treatment prior to
discontinuationa

All-cause mortality

Non-fatal and fatal
drug overdoseb,c

Non-fatal and fatal
opioid overdoseb−d

8–30 versus 31–90 

0.79 (0.55, 1.13)

1.07 (0.80, 1.41)

1.14 (0.69, 1.87)

8–30 versus 91–180

0.65 (0.42, 1.01)

0.93 (0.67, 1.31)

0.71 (0.42, 1.21)

8–30 versus 181–365

1.57 (0.80, 3.08)

1.86 (1.14, 3.04)

1.76 (0.75, 4.16)

31–90 versus 91–180

0.83 (0.52, 1.31)

0.88 (0.61, 1.27)

0.63 (0.35, 1.14)

31–90 versus 181–365

2.00 (1.01, 3.98)

1.75 (1.05, 2.91)

1.55 (0.63, 3.82)

91–180 versus 181–365 

2.42 (1.19, 4.95)

1.99 (1.17, 3.40)

2.47 (0.99, 6.14)

a

If individuals had more than one treatment episode between 2012 and 2018, the final one is analyzed.
Limited to the four sites with cause-of-death data (n = 3934).
c
Person-time censored at first overdose event after the final treatment episode; patients could not experience more than one overdose in the analysis.
d
Opioid overdoses include heroin and pharmaceutical opioid overdoses and are a subset of drug overdoses. CI = confidence interval.
b

T A B L E 4 Adjusted hazard ratios for associations between
buprenorphine treatment duration and all-cause mortality, drug
overdose, and opioid overdose after discontinuing buprenorphine,
using all buprenorphine treatment episodes
Outcome by duration of
buprenorphine treatment episode
(days)

In this multi-site cohort study, we examined the association between
different lengths of buprenorphine treatment and all-cause mortality
among patients who discontinued treatment. Mortality risks for treat-

Adjusted hazard ratio for all
treatment episodes (95% CI)a

All-cause mortalityb

ment durations of 8–30, 31–90, 91–180 and 181–365 days were not
significantly different to treatment durations of greater than 365 days.
In pairwise comparisons, treatment durations of 31–90 and 91–

8–30

1.07 (0.57, 2.02)

180 days were associated with increased risks compared to longer

31–90

1.40 (0.73, 2.68)

treatment durations of 181–365 days. These findings do not support

91–180

1.65 (0.84, 3.25)

time limits on buprenorphine treatment.

181–365

0.66 (0.28, 1.55)

> 365
Non-fatal and fatal drug overdose

1.00 (1.00, 1.00)

In post-hoc analyses, when compared to treatment durations of
6–12 months, treatment durations of 3–6 months were unexpectedly
associated with an increased incidence of all-cause mortality, drug

c,d

8–30

1.55 (0.99, 2.43)

31–90

1.30 (0.81, 2.08)

91–180

1.45 (0.89, 2.37)

181–365

1.02 (0.59, 1.78)

> 365

1.00 (1.00, 1.00)

Non-fatal and fatal opioid overdosec−e

a

DI SCU SSION

overdose and opioid overdose—findings that should be replicated in
future studies. If confirmed, future research should aim to understand
why people discontinue treatment after 3–6 months and why this
may be a period of heightened risk. One possible explanation is that,
after 3 months of treatment, patients may resume opioid use in new,
unfamiliar environments, which is thought to reduce tolerance and
increase the risk for overdose [7, 31]. Another possible explanation

8–30

2.19 (0.86, 5.60)

may relate to the evolving intensity of clinical monitoring and support

31–90

1.96 (0.74, 5.15)

in the early phases of treatment. For example, some subgroups of

91–180

2.55 (0.95, 6.82)

patients may be enrolled in intensive outpatient treatment during the

181–365

2.46 (0.87, 6.96)

first 30–90 days of treatment. If they continue to require more

> 365

1.00 (1.00, 1.00)

intensive support due to polysubstance use or psychiatric reasons,

If individuals had more than one treatment episode of 8 days or longer
during the study period, all episodes 8 days or longer are analyzed.
b
There were 9135 episodes of treatment across all sites.
c
Limited to the four sites with cause-of-death data (n = 5509 episodes).
d
Person-time censored at first overdose event after each treatment
episode; patients could not experience more than one overdose after each
treatment episode.
e
Opioid overdoses include heroin and pharmaceutical opioid overdoses
and are a subset of drug overdoses.

they may be at increased risk for adverse outcomes after intensive
outpatient treatment ends.
In this study, we were not able to determine why patients
stopped buprenorphine treatment. However, some patients may
have been involuntarily discontinued because they were subjected
to contracts and policies requiring frequent and costly urine toxicology monitoring, psychotherapy and follow-up visits. Given our
mortality findings, health systems should consider updating their
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policies on buprenorphine management, reducing patient treatment
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